1
|
Misaki K, Tamura N, Azuma T, Shinoda K, Tanaka M, Fujiwara H, Tsuboi H, Kasama T, Yoshimi R, Hanyu T, Kusaka Y, Hirao M, Onishi M, Uchino A, Izumiyama T, Yang KS, Ogawa N, Matsui K, Kurasawa K, Kawaai S, Yasuoka H, Okumura N, Ueda Y, Tanaka E, Inoue E, Tsuritani K, Matsumoto S, Yamanaka H, Harigai M. Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI). Mod Rheumatol 2024; 34:297-306. [PMID: 37233722 DOI: 10.1093/mr/road045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 04/13/2023] [Accepted: 04/21/2023] [Indexed: 05/27/2023]
Abstract
OBJECTIVES The aim of the article is to investigate the associations of disease duration and anti-cyclic citrullinated peptide antibody (ACPA) status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis (RA). METHODS We performed post hoc analyses of the Orencia® Registry in Geographically Assembled Multicenter Investigation (ORIGAMI) study of biologic-naïve RA patients aged ≥20 years with moderate disease activity who were prescribed abatacept. Changes in the Simplified Disease Activity Index (SDAI) and Japanese Health Assessment Questionnaire (J-HAQ) at 4, 24, and 52 weeks of treatment were analysed in patients divided according to ACPA serostatus (positive/negative), disease duration (<1/≥1 year), or both. RESULTS SDAI scores decreased from baseline in all groups. SDAI scores tended to decrease more in the ACPA-positive group and disease duration <1-year group than in the ACPA-negative group and disease duration ≥1-year group, respectively. In the disease duration <1-year group, SDAI tended to decrease more in the ACPA-positive group than in the ACPA-negative group. Disease duration was independently associated with the change in SDAI and SDAI remission at Week 52 in multivariable regression models. CONCLUSIONS These results suggest that starting abatacept within 1 year of diagnosis was associated with greater effectiveness of abatacept in biologic-naïve patients with RA and moderate disease activity.
Collapse
Affiliation(s)
- Kenta Misaki
- Department of Rheumatology, Kita-Harima Medical Center, Hyogo, Japan
| | - Naoto Tamura
- Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
| | | | - Koichiro Shinoda
- First Department of Internal Medicine, University of Toyama, Toyama, Japan
| | - Masao Tanaka
- Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Hiroshi Fujiwara
- Division of Rheumatology, Osaka General Medical Center, Osaka, Japan
| | - Hideki Tsuboi
- Department of Orthopaedic Surgery, Osaka Rosai Hospital, Osaka, Japan
| | - Tsuyoshi Kasama
- Department of Rheumatology, Showa University Koto Toyosu Hospital, Tokyo, Japan
| | - Ryusuke Yoshimi
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Kanagawa, Japan
| | - Tadamasa Hanyu
- Department of Rheumatology, Nagaoka Red Cross Hospital, Niigata, Japan
| | - Yoshiaki Kusaka
- Department of Orthopaedic Surgery, Asahi University Hospital, Gifu, Japan
| | - Makoto Hirao
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Makoto Onishi
- Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Ehime, Japan
| | - Ayumi Uchino
- Department of Rheumatology, Aso Iizuka Hospital, Fukuoka, Japan
| | | | - Kwang-Seok Yang
- Department of Geriatric General Medicine, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Noriyoshi Ogawa
- Department of Internal Medicine 3, Hamamatsu University School of Medicine, Shizuoka, Japan
| | - Kiyoshi Matsui
- Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
| | - Kazuhiro Kurasawa
- Department of Rheumatology, Dokkyo Medical University, Tochigi, Japan
| | - Satoshi Kawaai
- Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
| | - Hidekata Yasuoka
- Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine, Aichi, Japan
| | - Noriaki Okumura
- Department of Orthopaedic Surgery, Shiga University of Medical Science, Shiga, Japan
| | - Yo Ueda
- Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Hyogo, Japan
| | - Eiichi Tanaka
- Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| | - Eisuke Inoue
- Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
- Showa University Research Administration Center, Showa University, Tokyo, Japan
| | - Katsuki Tsuritani
- Department of Immunology Medical, Bristol-Myers Squibb, Tokyo, Japan
| | | | - Hisashi Yamanaka
- Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
- Department of Rheumatology, Sanno Medical Center, Tokyo, Japan
| | - Masayoshi Harigai
- Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| |
Collapse
|
2
|
Maeda K, Tanioka T, Takahashi R, Watanabe H, Sueki H, Takimoto M, Hashimoto SI, Ikeo K, Miwa Y, Kasama T, Iwamoto S. MCAM+CD161- Th17 Subset Expressing CD83 Enhances Tc17 Response in Psoriasis. J Immunol 2023; 210:1867-1881. [PMID: 37186262 DOI: 10.4049/jimmunol.2200530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Accepted: 03/27/2023] [Indexed: 05/17/2023]
Abstract
Recent studies have highlighted the pathogenic roles of IL-17-producing CD8+ T cells (T-cytotoxic 17 [Tc17]) in psoriasis. However, the underlying mechanisms of Tc17 induction remain unclear. In this study, we focused on the pathogenic subsets of Th17 and their mechanism of promotion of Tc17 responses. We determined that the pathogenic Th17-enriched fraction expressed melanoma cell adhesion molecule (MCAM) and CCR6, but not CD161, because this subset produced IL-17A abundantly and the presence of these cells in the peripheral blood of patients has been correlated with the severity of psoriasis. Intriguingly, the serial analysis of gene expression revealed that CCR6+MCAM+CD161-CD4+ T cells displayed the gene profile for adaptive immune responses, including CD83, which is an activator for CD8+ T cells. Coculture assay with or without intercellular contact between CD4+ and CD8+ T cells showed that CCR6+MCAM+CD161-CD4+ T cells induced the proliferation of CD8+ T cells in a CD83-dependent manner. However, the production of IL-17A by CD8+ T cells required exogenous IL-17A, suggesting that intercellular contact via CD83 and the production of IL-17A from activated CD4+ T cells elicit Tc17 responses. Intriguingly, the CD83 expression was enhanced in the presence of IL-15, and CD83+ cells stimulated with IL-1β, IL-23, IL-15, and IL-15Rα did not express FOXP3. Furthermore, CCR6+MCAM+CD161-CD4+ T cells expressing CD83 were increased in the peripheral blood of patients, and the CD83+ Th17-type cells accumulated in the lesional skin of psoriasis. In conclusion, pathogenic MCAM+CD161- Th17 cells may be involved in the Tc17 responses via IL-17A and CD83 in psoriasis.
Collapse
Affiliation(s)
- Kohei Maeda
- Division of Physiology and Pathology, Department of Pharmacology, Toxicology, and Therapeutics, Showa University School of Pharmacy, Tokyo, Japan
| | - Toshihiro Tanioka
- Division of Physiology and Pathology, Department of Pharmacology, Toxicology, and Therapeutics, Showa University School of Pharmacy, Tokyo, Japan
| | - Rei Takahashi
- Division of Physiology and Pathology, Department of Pharmacology, Toxicology, and Therapeutics, Showa University School of Pharmacy, Tokyo, Japan
| | - Hideaki Watanabe
- Department of Dermatology, Showa University School of Medicine, Tokyo, Japan
| | - Hirohiko Sueki
- Department of Dermatology, Showa University School of Medicine, Tokyo, Japan
| | - Masafumi Takimoto
- Department of Pathology and Laboratory Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Shin-Ichi Hashimoto
- Department of Molecular Pathophysiology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan
| | - Kazuho Ikeo
- DNA Data Analysis Laboratory, National Institute of Genetics, Shizuoka, Japan
| | - Yusuke Miwa
- Department of Internal Medicine, Division of Rheumatology, Showa University School of Medicine, Tokyo, Japan
| | - Tsuyoshi Kasama
- Department of Internal Medicine, Division of Rheumatology, Showa University School of Medicine, Tokyo, Japan
| | - Sanju Iwamoto
- Division of Physiology and Pathology, Department of Pharmacology, Toxicology, and Therapeutics, Showa University School of Pharmacy, Tokyo, Japan
| |
Collapse
|
3
|
Yajima N, Kawaguchi T, Takahashi R, Nishiwaki H, Toyoshima Y, Oh K, Odai T, Kanai T, Morisky DE, Yamaguchi T, Kasama T. Adherence to methotrexate and associated factors considering social desirability in patients with rheumatoid arthritis: a multicenter cross-sectional study. BMC Rheumatol 2022; 6:75. [PMID: 36527156 PMCID: PMC9758812 DOI: 10.1186/s41927-022-00305-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Accepted: 09/08/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Assessing medication adherence in rheumatoid arthritis (RA) is clinically significant as low adherence is associated with high disease activity. Self-reported medication adherence surveys have been shown to have problems with overestimation of adherence due to social desirability bias. However, no MTX adherence studies adjusted for social desirability have been conducted to date. This study aimed to evaluate adherence to MTX and perform an investigatory search for factors associated with MTX adherence including social desirability. METHODS This cross-sectional multicenter study was conducted among adult RA patients consuming oral MTX for ≥ 3 months. We examined the distribution of MTX adherence, according to the eight-item Morisky Medication Adherence Scale (MMAS-8). Social desirability was using the Social Desirability Scale (SDS). Furthermore, an exploratory factor analysis involving social desirability was examined to identify factors associated with MTX adherence using linear regression analysis. To deal with missing values, we used multiple imputations with chained equations methods. RESULTS A total of 165 RA patients were enrolled. The median age was 64 years, and 86.1% were women. Based on the MMAS-8, low, medium, and high adherences were noted in 12.1%, 60.0%, and 27.9% of participants, respectively. High social desirability (coefficient, 0.14; 95% confidence interval [CI], 0.05-0.23; p < 0.05) and high age (coefficient per 10 years, 0.16; 95% CI, 0.01-0.03; p < 0.05) were associated with high MTX adherence, whereas full-time work was negatively associated with high MTX adherence (coefficient, -0.50; 95% CI, -0.95--0.05; p < 0.05). CONCLUSIONS A large proportion of patients with RA do not take MTX as prescribed. High social desirability, high educational level, and non-full-time work may be associated with high MTX adherence. Physicians should confirm MTX adherence before switching or adding disease-modifying anti-rheumatic drugs in cases of uncontrolled disease activity.
Collapse
Affiliation(s)
- Nobuyuki Yajima
- grid.410714.70000 0000 8864 3422Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666 Japan ,grid.258799.80000 0004 0372 2033Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan ,grid.411582.b0000 0001 1017 9540Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, Fukushima, Japan
| | - Takashi Kawaguchi
- grid.410785.f0000 0001 0659 6325Department of Practical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
| | - Ryo Takahashi
- grid.410714.70000 0000 8864 3422Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666 Japan
| | - Hiroki Nishiwaki
- grid.412808.70000 0004 1764 9041Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan ,grid.410714.70000 0000 8864 3422Showa University Research Administration Center, Tokyo, Japan
| | - Yoichi Toyoshima
- grid.412812.c0000 0004 0443 9643Department of Orthopedic Surgery, Showa University Toyosu Hospital, Tokyo, Japan
| | - Koei Oh
- grid.482675.a0000 0004 1768 957XDepartment of Orthopedic Surgery, Showa University Northern Yokohama Hospital, Yokohama, Japan
| | - Tsuyoshi Odai
- grid.482675.a0000 0004 1768 957XDepartment of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan ,Department of Rheumatology, Yokohama Asahi Central General Hospital, Kanagawa, Japan
| | - Takayuki Kanai
- Department of Nephrology, Kanto Rosai Hospital, Kawasaki, Japan
| | - Donald E. Morisky
- grid.19006.3e0000 0000 9632 6718Department of Community Health Sciences, UCLA Fielding School of Public Health, Los Angeles, USA
| | - Takuhiro Yamaguchi
- grid.69566.3a0000 0001 2248 6943Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, Japan
| | - Tsuyoshi Kasama
- grid.410714.70000 0000 8864 3422Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666 Japan
| |
Collapse
|
4
|
Hosonuma M, Isozaki T, Furuya H, Yamazaki Y, Ikari Y, Nishimi S, Ishii S, Maeoka A, Tokunaga T, Wakabayashi K, Konishi N, Fukuse S, Ishikawa K, Sakai N, Inagaki K, Kasama T. AB0065 HGF/C-MET SIGNALING PROMOTE ANGIOGENESIS THROUGH CXCL16 IN RHEUMATOID ARTHRITIS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Hepatocyte growth factor (HGF) binds to the receptor tyrosine kinase c-Met and is a multifunctional cytokine that promotes processes such as cell proliferation, survival, differentiation, migration and angiogenesis [1]. We previously reported that HGF is produced by inflammation in the RA synovium, and activates monocyte migration to the synovium and promotes bone destruction through its own chemotactic effect and enhanced chemokine production in the synovium [2].Objectives:Therefore, we next aimed to determine the role of HGF in RA angiogenesis.Methods:The expression of HGF / c-Met in the serum and synovial tissues (STs) of RA patients and controls and human umbilical vein endothelial cells (HUVECs) was evaluated by ELISA and immunostaining. The effect of HGF/c-Met signaling on the promotion of CXCL16 production from HUVECs and RA fibroblast-like synoviocytes (FLSs) was determined by ELISA. To examine the role of HGF in angiogenesis, we performed in vitro Matrigel assays using HUVECs treated with HGF.Results:HGF in serum in treatment-naive RA patients was significantly higher than that in controls and HGF in serum in treatment-resistant RA showed a significant positive correlation with CXCL16. c-Met were expressed on vascular endothelial cells of RA STs and HUVECs. Stimulation of HUVECs with HGF dose-dependently increased CXCL16 production. c-Met signal inhibition by SU11274 suppressed TNF-α stimulation-enhanced CXCL16 production by RA FLSs in a dose-dependent manner. Furthermore, HGF induced HUVEC tube formation by 1.8-fold.Conclusion:HGF is produced by inflammation in the RA synovium, and activates angiogenesis through its own potent angiogenic effect and enhanced production of CXCL16 in the synovium. These results indicate that a strategy targeting c-Met signalling may be important for resolving treatment-resistant RA.References:[1]Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989 Nov 23;342(6248):440-3.[2]Hosonuma M, Sakai N, Furuya H, et al. Inhibition of hepatocyte growth factor/c-Met signalling abrogates joint destruction by suppressing monocyte migration in rheumatoid arthritis. Rheumatology (Oxford). 2021 Jan 5;60(1):408-419.Disclosure of Interests:None declared
Collapse
|
5
|
Hosonuma M, Isozaki T, Furuya H, Yamazaki Y, Ikari Y, Nishimi S, Maeoka A, Ishii S, Tokunaga T, Wakabayashi K, Konishi N, Fukuse S, Ishikawa K, Sakai N, Inagaki K, Kasama T. POS0429 INTERLEUKIN-4 ACTIVATES EOSINOPHILS AND CCR3-POSITIVE T HELPER CELLS MIGRATION TO FASCIA AND PROMOTES FIBROSIS IN EOSINOPHILIC FASCIITIS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Eosinophilic fasciitis (EF) is a rare disease that causes inflammation and fibrosis mainly in the fascia of the extremities with eosinophilia. It has been reported that the hypertrophied fascia in EF shows inflammatory cell infiltration by the lymphocytes and eosinophils and increased expression of fibrosis-related cytokines genes in fibroblast [1]. However, its pathophysiology in the fascia remains unresolved.Objectives:Therefore, we focused on fascial fibroblasts and aimed to determine the role of interleukin-4 (IL-4) in eosinophil and helper T cell infiltration and fibrosis in fascial fibroblast in EF.Methods:Fascial fibroblasts were obtained from fascia biopsy of a patient with EF, and were stimulated with pre- and post-treatment serum of a patient with EF and healthy control, followed by microarray to analyze gene expression. Fascial fibroblasts were stimulated with IL-4 10 ng/mL, and gene expression of IL-4 receptor and CCR3 ligands, CCL7 and CCL11 were measured by qPCR. Transforming growth factor (TGF) -β and periostin in the pre- and post-treatment serum of a patient with EF and conditioned medium of fascial fibroblasts stimulated with IL-4 were measured by ELISA. To examine the role of IL-4 in proliferation, we performed in proliferation assays using fascial fibroblasts treated with IL-4. CCR3-positive T cells in the fascial tissue of EF, dermatomyositis, and polymyositis patients were evaluated by immunostaining.Results:By microarray analysis, CCL7 and CCL11 expression of fascial fibroblasts stimulated with pre-treatment EF serum was higher than that in post-treatment EF serum and control serum. CCL7 and CCL11 mRNA in IL-4 stimulated facial fibroblasts were increased by 5.1-fold and 7.3-fold, respectively. TGF-β and periostin in IL-4 stimulated facial fibroblast conditioned medium were also increased. In addition, TGF-β and periostin in EF serum were gradually decreased by treatment for 4 and 10 weeks, compared to before treatment. Finally, fascial fibroblast proliferation was significantly increased by stimulation with IL-4. Furthermore, infiltration of CCR3-positive T cells was specific to the fascial tissue of EF.Conclusion:In EF, IL-4 enhances the production of CCR3 ligands, TGF-β, and periostin from fascial fibroblasts. As a result, it promotes the migration of eosinophils and CCR3-positive T helper cells to the fascia and fibrosis. These results suggest that inhibition of IL-4 pathway could be a novel strategy for eosinophilic fasciitis.References:[1]Igarashi A, Nashiro K, Kikuchi K, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol. 1996 Apr;106(4):729-33.Disclosure of Interests:None declared
Collapse
|
6
|
Wakabayashi K, Isozaki T, Tsubokura Y, Fukuse S, Kasama T. Eotaxin-1/CCL11 is involved in cell migration in rheumatoid arthritis. Sci Rep 2021; 11:7937. [PMID: 33846499 PMCID: PMC8041786 DOI: 10.1038/s41598-021-87199-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Accepted: 03/22/2021] [Indexed: 12/29/2022] Open
Abstract
Eotaxin-1 (CCL11) induces the migration of different leukocyte types by interacting with CCR3. In rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) are pathogenic effectors and a major CCR3-expressing cell. The aim of this study was to investigate the expression and function of CCL11 in RA FLS. The expression of CCL11 and CCR3 was evaluated by ELISA, immunofluorescence and quantitative PCR analysis. The CCL11 levels in serum and synovial fluids (SFs) from RA patients were significantly higher than those in serum from healthy controls and SFs from osteoarthritis patients. CCL11 and CCR3 were expressed in the RA synovial tissue lining layers. The secretion of CCL11 in RA FLS-conditioned medium and the mRNA expression of CCL11 and CCR3 were induced by TNF-α. Furthermore, CCL11 induced the mRNA expression of CCL11 and CCR3. Application of a CCR3 antagonist reduced TNF-α-induced CCL11 secretion from RA FLS. CCL11 induced the migration of RA FLS and monocytes. RA FLS migration was decreased by treatment with CCL11 siRNA. The migration of monocytes to medium conditioned with CCL11 siRNA-transfected and TNF-α-stimulated RA FLS was reduced. These data indicate that the self-amplification of CCL11 via CCR3 may play an important role in cell migration in RA.
Collapse
Affiliation(s)
- Kuninobu Wakabayashi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan.
| | - Takeo Isozaki
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan
| | - Yumi Tsubokura
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan
| | - Sayaka Fukuse
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan
| |
Collapse
|
7
|
Hosonuma M, Sakai N, Furuya H, Kurotaki Y, Sato Y, Handa K, Dodo Y, Ishikawa K, Tsubokura Y, Negishi-Koga T, Tsuji M, Kasama T, Kiuchi Y, Takami M, Isozaki T. Inhibition of hepatocyte growth factor/c-Met signalling abrogates joint destruction by suppressing monocyte migration in rheumatoid arthritis. Rheumatology (Oxford) 2021; 60:408-419. [PMID: 32770199 DOI: 10.1093/rheumatology/keaa310] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2020] [Revised: 04/25/2020] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVES To determine the expression of hepatocyte growth factor (HGF) in RA biological fluids, the role of HGF in monocyte migration and the therapeutic effect of the c-Met inhibitor savolitinib in an arthritis model mice. METHODS HGF/c-Met expression in serum, SF and synovial tissues (STs) obtained from RA patients and controls, as well as RA fibroblast-like synoviocytes (FLSs), was evaluated by ELISA and immunostaining. To determine the function of HGF in RA SF, we preincubated RA SF with a neutralizing anti-HGF antibody and measured the chemotactic ability of a human acute monocytic leukaemia cell line (THP-1). Additionally, examinations were conducted of SKG mice treated with savolitinib for 4 weeks. RESULTS HGF levels in serum from RA patients were significantly higher than those in the controls and were decreased by drug treatment for 24 weeks. Additionally, the HGF level in SF from RA patients was higher than that in SF from OA patients. HGF and c-Met expression was also noted in RA STs. Stimulation of RA FLSs with TNF-α increased HGF/c-Met expression in a concentration-dependent manner, and c-Met signal inhibition suppressed production of fractalkine/CX3CL1 and macrophage inflammatory protein-1α/CCL3. When HGF was removed by immunoprecipitation, migration of THP-1 in RA SF was suppressed. In SKG mice, savolitinib significantly suppressed ankle bone destruction on µCT, with an associated reduction in the number of tartrate-resistant acid phosphatase-positive osteoclasts. CONCLUSION HGF produced by inflammation in synovium of RA patients activates monocyte migration to synovium and promotes bone destruction via a chemotactic effect and enhanced chemokine production.
Collapse
Affiliation(s)
- Masahiro Hosonuma
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa.,Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Shinagawa.,Department of Pharmacology, Showa University School of Dentistry, Shinagawa.,Parmacological Research Center, Showa University, Shinagawa
| | - Nobuhiro Sakai
- Department of Pharmacology, Showa University School of Dentistry, Shinagawa.,Parmacological Research Center, Showa University, Shinagawa
| | - Hidekazu Furuya
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa
| | - Yutaro Kurotaki
- Department of Pharmacology, Showa University School of Dentistry, Shinagawa.,Parmacological Research Center, Showa University, Shinagawa.,Division of Community-Based Comprehensive Dentistry, Department of Special Needs Dentistry, School of Dentistry, Showa University, Ota
| | - Yurie Sato
- Department of Pharmacology, Showa University School of Dentistry, Shinagawa.,Parmacological Research Center, Showa University, Shinagawa.,Division of Dentistry for Persons with Disabilities, School of Dentistry, Showa University, Ota
| | - Kazuaki Handa
- Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Shinagawa.,Department of Pharmacology, Showa University School of Dentistry, Shinagawa.,Parmacological Research Center, Showa University, Shinagawa.,Department of Orthopaedic Surgery, Showa University School of Medicine, Shinagawa
| | - Yusuke Dodo
- Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Shinagawa.,Department of Pharmacology, Showa University School of Dentistry, Shinagawa.,Parmacological Research Center, Showa University, Shinagawa.,Department of Orthopaedic Surgery, Showa University School of Medicine, Shinagawa
| | - Koji Ishikawa
- Parmacological Research Center, Showa University, Shinagawa.,Department of Orthopaedic Surgery, Showa University School of Medicine, Shinagawa
| | - Yumi Tsubokura
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa
| | - Takako Negishi-Koga
- Department of Pharmacology, Showa University School of Dentistry, Shinagawa.,Parmacological Research Center, Showa University, Shinagawa.,Division of Mucosal Barriology, International Research and Development Centre for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Minato, Tokyo, Japan
| | - Mayumi Tsuji
- Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Shinagawa.,Parmacological Research Center, Showa University, Shinagawa
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa
| | - Yuji Kiuchi
- Division of Medical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Shinagawa.,Parmacological Research Center, Showa University, Shinagawa
| | - Masamichi Takami
- Department of Pharmacology, Showa University School of Dentistry, Shinagawa.,Parmacological Research Center, Showa University, Shinagawa
| | - Takeo Isozaki
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa
| |
Collapse
|
8
|
Nagaoka S, Katayama K, Kasama T, Sato M, Ohno S, Amasaki Y, Kataoka H, Furusaki A, Kon Y, Okamoto M, Sasano M, Sagawa A. Weekly split-dose regimen for oral methotrexate reduced polyglutamation in red blood cells in patients with rheumatoid arthritis compared with single-dose regimen: Results from a multicentered randomized control trial. Int J Rheum Dis 2020; 23:1328-1336. [PMID: 32896992 DOI: 10.1111/1756-185x.13931] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Revised: 06/25/2020] [Accepted: 07/13/2020] [Indexed: 11/28/2022]
Abstract
AIMS We compared the incidence of adverse events between single and divided-dose regimens of methotrexate (MTX) by using a multicenter randomized controlled trial. METHODS Eighty-nine patients with insufficient control on MTX 8 mg/wk were randomly assigned into single-dose (39 patients) or triple dose (39 patients) groups. The MTX dose for all patients was gradually increased to 16 mg/wk. The primary endpoint was the occurrence of liver dysfunction during the observation period (20 weeks). RESULTS There were no differences in baseline data and MTX dose at Week 20 between groups. There was no significant difference in the incidence of liver dysfunction between groups (single dose, 3 [7.7%] patients vs. triple dose, 5 [13.2%] patients; P = .455). The incidence of adverse event increased in triple dose (single dose, 12 [30.8%] patients vs. triple dose, 20 [51.3%]), but the difference was not significant (P = .066). There was no significant difference in disease activity between groups, although MTX-triglutamate (PG3), MTX-PG4, and MTX-PG5 were significantly higher in the single dose group. CONCLUSIONS Weekly split dosing reduced the polyglutamation of MTX. There was no significant difference in efficacy and safety between the 2 groups.
Collapse
Affiliation(s)
- Shouhei Nagaoka
- Yokohama Minami Kyosai Hospital, Yokohama city, Kanagawa, Japan
| | - Kou Katayama
- Katayama Orthopedic Rheumatology Clinic, Asahikawa city, Hokkaido, Japan
| | | | - Masao Sato
- Ohashi Tani Orthopedics, Gifu city, Gifu, Japan
| | - Shigeru Ohno
- Yokohama City University Medical Center, Yokohama city, Kanagawa, Japan
| | | | | | - Akira Furusaki
- KKR Sapporo Medical Center, Sapporo, Japan.,Sagawa Akira Rheumatology Clinic, Sapporo city, Hokkaido, Japan
| | - Yujiro Kon
- Katayama Orthopedic Rheumatology Clinic, Asahikawa city, Hokkaido, Japan.,Sapporo Rheumatology and immunology clinic, Sapporo city, Hokkaido, Japan
| | | | | | - Akira Sagawa
- Sagawa Akira Rheumatology Clinic, Sapporo city, Hokkaido, Japan
| |
Collapse
|
9
|
Matoba M, Suzuki T, Ochiai H, Shirasawa T, Yoshimoto T, Minoura A, Sano H, Ishii M, Kokaze A, Otake H, Kasama T, Kamijo Y. Seven-day services in surgery and the "weekend effect" at a Japanese teaching hospital: a retrospective cohort study. Patient Saf Surg 2020; 14:24. [PMID: 32518591 PMCID: PMC7271452 DOI: 10.1186/s13037-020-00250-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2019] [Accepted: 05/27/2020] [Indexed: 11/10/2022] Open
Abstract
Background Hospitals deliver 24-h, 7-day care on a 5-day workweek model, as fewer resources are available on weekends. In prior studies, poorer outcomes have been observed with weekend admission or surgery. The purpose of this study was to investigate the effect of 7-day service at a hospital, including outpatient consultations, diagnostic examinations and elective surgeries, on the likelihood of the “weekend effect” in surgery. Methods This was a retrospective cohort study of patients who underwent surgery between April 2014 and October 2016 at an academic medical centre in Tokyo, Japan. The main outcome measure was 30-day in-hospital mortality from the index surgery. The characteristics of the participants were compared using the Mann–Whitney U test or the chi-squared test as appropriate. Logistic regression was used to test for differences in the mortality rate between the two groups, and propensity score adjustments were made. Results A total of 7442 surgeries were identified, of which, 1386 (19%) took place on the weekend. Of the 947 emergency surgeries, 25% (235) were performed on the weekend. The mortality following emergency weekday surgery was 21‰ (15/712), compared with 55‰ (13/235) following weekend surgery. Of the 6495 elective surgeries, 18% (1151) were performed on the weekend. The mortality following elective weekday surgery was 2.3‰ (12/5344), compared with 0.87‰ (1/1151) following weekend surgery. After adjustment, weekend surgeries were associated with an increased risk of death, especially in the emergency setting (emergency odds ratio: 2.7, 95% confidence interval: 1.2–6.5 vs. elective odds ratio: 0.4, 95% confidence interval: 0.05–3.2). Conclusions Patients undergoing emergency surgery on the weekend had higher 30-day mortality, but showed no difference in elective surgery mortality. These findings have potential implications for health administrators and policy makers who may try to restructure the hospital workweek or consider weekend elective surgery.
Collapse
Affiliation(s)
- Masaaki Matoba
- Department of Health Management, Showa University Graduate School of Health Sciences, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan.,Department of Hygiene, Public Health and Preventive Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Takashi Suzuki
- Department of Anesthesiology, Showa University Koto Toyosu Hospital, 5-1-38 Toyosu, Koto-ku, Tokyo, 135-8577 Japan
| | - Hirotaka Ochiai
- Department of Hygiene, Public Health and Preventive Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Takako Shirasawa
- Department of Hygiene, Public Health and Preventive Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Takahiko Yoshimoto
- Department of Hygiene, Public Health and Preventive Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Akira Minoura
- Department of Hygiene, Public Health and Preventive Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Hitomi Sano
- Department of Anesthesiology, Showa University Koto Toyosu Hospital, 5-1-38 Toyosu, Koto-ku, Tokyo, 135-8577 Japan
| | - Mizue Ishii
- Department of Anesthesiology, Showa University Koto Toyosu Hospital, 5-1-38 Toyosu, Koto-ku, Tokyo, 135-8577 Japan
| | - Akatsuki Kokaze
- Department of Hygiene, Public Health and Preventive Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Hiroshi Otake
- Department of Anesthesiology and Critical Care Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Tsuyoshi Kasama
- Department of Rheumatology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| | - Yumi Kamijo
- Department of Health Management, Showa University Graduate School of Health Sciences, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan
| |
Collapse
|
10
|
Hosonuma M, Sakai N, Furuya H, Tsubokura Y, Nishimi S, Ikari Y, Ishii S, Maeoka A, Tokunaga T, Wakabayashi K, Kasama T, Takami M, Isozaki T. SAT0005 INHIBITION OF HEPATOCYTE GROWTH FACTOR/C-MET SIGNALING ABROGATES JOINT DESTRUCTION BY SUPPRESSING MIGRATION OF MONOCYTES TO SYNOVIUM IN RHEUMATOID ARTHRITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Hepatocyte growth factor (HGF), originally discovered as a mitogen of hepatocytes, binds to receptor-tyrosine kinase c-Met and has been shown to be a multi-functional cytokine that promotes processes such as cell proliferation, survival, differentiation, migration, and angiogenesis1. Since HGF/c-Met signaling also leads to tumorigenesis and cancer invasion, that has recently attracted attention as a target for anticancer agents2. However, in reports of rheumatoid arthritis (RA), though anti-inflammatory and antiangiogenic mechanisms related to HGF/c-Met signal inhibition have been reported, the role of HGF in RA bone destruction through monocyte migration remains unclear3.Objectives:To determine the expression of HGF in RA biological fluids, the role it plays in monocyte migration and the therapeutic effect of a savolitinib, a specific c-Met inhibitor, in arthritis model mice.Methods:HGF/c-Met expression in serum, synovial fluid (SF), and synovial tissues (STs) obtained from RA patients and control subjects, as well as RA fibroblast-like synoviocytes (FLSs) was evaluated by ELISA and immunostaining. To determine the function of HGF in RA SFs, we preincubated RA SFs with a neutralizing anti-HGF antibody and measured the ability of these SFs to induce the human acute monocytic leukemia cell line (THP-1) chemotaxis. Additionally, examinations of SKG mice treated with savolitinib (2.5 mg/kg/day) for 4 weeks were conducted.Results:HGF level in serum from RA patients was significantly higher as compared to the controls (930 ± 97 vs. 476 ± 97 pg/mL, p <0.01) and decreased by drug treatment for 24 weeks (1147 ± 284 vs. 539 ± 160 pg/mL, p <0.05). Additionally, HGF level in SF from RA patients was higher as compared to SF from osteoarthritis patients (1632 ± 366 vs. 566 ± 140 pg/mL, p <0.05). HGF and c-Met expressions were also noted in RA STs. Stimulation of RA-FLS with TNF-α increased HGF/c-Met expression in a concentration-dependent manner, and c-Met signal inhibition by SU11274 suppressed production of fractalkine/CX3CL1, CXCL16, and MIP-1α/CCL3 (mean 50%, 56%, 90%, respectively). When HGF was removed by immunoprecipitation, migration of THP-1 in RA-SF was suppressed (mean 23%). In SKG mice, savolitinib significantly suppressed ankle bone damage on µCT, with an associated reduction in number of tartrate-resistant acid phosphatase-positive osteoclasts.Conclusion:HGF is produced by inflammation in synovium associated with RA, and then activates monocyte migration to synovium tissue and promotes bone destruction through its own chemotactic effect as well as enhanced chemokine production. These results indicate that a strategy that targets c-Met signaling may be important for resolving bone destruction in RA.References:[1] Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989 Nov 23;342(6248):440-3[2] Lee D, Sung ES, Ahn JH, An S, Huh J, You WK. Development of antibody-based c-Met inhibitors for targeted cancer therapy. Immunotargets Ther. 2015 Feb 9;4:35-44.[3] Koch AE, Halloran MM, Hosaka S, Shah MR, Haskell CJ, Baker SK, Panos RJ, Haines GK, Bennett GL, Pope RM, Ferrara N. Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis. Arthritis Rheum. 1996 Sep;39(9):1566-75Disclosure of Interests:None declared
Collapse
|
11
|
Svensson MND, Zoccheddu M, Yang S, Nygaard G, Secchi C, Doody KM, Slowikowski K, Mizoguchi F, Humby F, Hands R, Santelli E, Sacchetti C, Wakabayashi K, Wu DJ, Barback C, Ai R, Wang W, Sims GP, Mydel P, Kasama T, Boyle DL, Galimi F, Vera D, Tremblay ML, Raychaudhuri S, Brenner MB, Firestein GS, Pitzalis C, Ekwall AKH, Stanford SM, Bottini N. Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal. Sci Adv 2020; 6:eaba4353. [PMID: 32637608 PMCID: PMC7319753 DOI: 10.1126/sciadv.aba4353] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Accepted: 04/20/2020] [Indexed: 06/11/2023]
Abstract
Fibroblast-like synoviocytes (FLS) are joint-lining cells that promote rheumatoid arthritis (RA) pathology. Current disease-modifying antirheumatic agents (DMARDs) operate through systemic immunosuppression. FLS-targeted approaches could potentially be combined with DMARDs to improve control of RA without increasing immunosuppression. Here, we assessed the potential of immunoglobulin-like domains 1 and 2 (Ig1&2), a decoy protein that activates the receptor tyrosine phosphatase sigma (PTPRS) on FLS, for RA therapy. We report that PTPRS expression is enriched in synovial lining RA FLS and that Ig1&2 reduces migration of RA but not osteoarthritis FLS. Administration of an Fc-fusion Ig1&2 attenuated arthritis in mice without affecting innate or adaptive immunity. Furthermore, PTPRS was down-regulated in FLS by tumor necrosis factor (TNF) via a phosphatidylinositol 3-kinase-mediated pathway, and TNF inhibition enhanced PTPRS expression in arthritic joints. Combination of ineffective doses of TNF inhibitor and Fc-Ig1&2 reversed arthritis in mice, providing an example of synergy between FLS-targeted and immunosuppressive DMARD therapies.
Collapse
Affiliation(s)
- Mattias N. D. Svensson
- Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA
- Division of Cellular Biology, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| | - Martina Zoccheddu
- Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA
| | - Shen Yang
- Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA
| | - Gyrid Nygaard
- Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA
| | - Christian Secchi
- Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA
- Division of Cellular Biology, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
- Department of Biomedical Sciences, National Institute of Biostructures and Biosystems, University of Sassari Medical School, 07100 Sassari, Italy
| | - Karen M. Doody
- Division of Cellular Biology, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| | - Kamil Slowikowski
- Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA
- Division of Genetics, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA
- Partners HealthCare Personalized Medicine, Boston, MA 02115, USA
- Program in Medical and Population Genetics, Broad Institute of Massachusetts Technical Institute and Harvard University, Cambridge, MA 02138, USA
- Bioinformatics and Integrative Genomics, Harvard University, Cambridge, MA 02138, USA
| | - Fumitaka Mizoguchi
- Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA
- Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8519, Japan
| | - Frances Humby
- Centre for Experimental Medicine and Rheumatology, John Vane Science Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Rebecca Hands
- Centre for Experimental Medicine and Rheumatology, John Vane Science Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Eugenio Santelli
- Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA
- Division of Cellular Biology, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| | - Cristiano Sacchetti
- Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA
- Division of Cellular Biology, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| | - Kuninobu Wakabayashi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
| | - Dennis J. Wu
- Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA
| | - Christopher Barback
- Department of Radiology, University of California, La Jolla, CA 92093, USA
- UCSD Molecular Imaging Program, University of California, La Jolla, CA 92093, USA
| | - Rizi Ai
- Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093, USA
| | - Wei Wang
- Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093, USA
| | - Gary P. Sims
- Respiratory, Inflammation and Autoimmunity, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA
| | - Piotr Mydel
- Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, The Laboratory Building, 5th Floor, 5021 Bergen, Norway
- Department of Microbiology, Jagiellonian University, Kraków, Poland
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
| | - David L. Boyle
- Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA
| | - Francesco Galimi
- Department of Biomedical Sciences, National Institute of Biostructures and Biosystems, University of Sassari Medical School, 07100 Sassari, Italy
| | - David Vera
- Department of Radiology, University of California, La Jolla, CA 92093, USA
- UCSD Molecular Imaging Program, University of California, La Jolla, CA 92093, USA
| | - Michel L. Tremblay
- Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, Québec H3A 1A3, Canada
- Department of Biochemistry, McGill University, Montréal, Québec H3A 1A3, Canada
- Department of Medicine, Division of Experimental Medicine, McGill University, Montréal, Québec H3A 1A3, Canada
| | - Soumya Raychaudhuri
- Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA
- Division of Genetics, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA
- Partners HealthCare Personalized Medicine, Boston, MA 02115, USA
- Program in Medical and Population Genetics, Broad Institute of Massachusetts Technical Institute and Harvard University, Cambridge, MA 02138, USA
- Rheumatology Unit, Karolinska Institutet, Stockholm S-171 76, Sweden
- Institute of Inflammation and Repair, University of Manchester, Manchester M13 9PT, UK
| | - Michael B. Brenner
- Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA
| | - Gary S. Firestein
- Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA
| | - Costantino Pitzalis
- Centre for Experimental Medicine and Rheumatology, John Vane Science Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
| | - Anna-Karin H. Ekwall
- Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Centre for Bone and Arthritis Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Stephanie M. Stanford
- Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA
- Division of Cellular Biology, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| | - Nunzio Bottini
- Department of Medicine, Altman Clinical and Translational Research Institute, University of California, San Diego, La Jolla, CA 92093, USA
- Division of Cellular Biology, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
| |
Collapse
|
12
|
Kato Y, Kasama T, Soejima M, Kubota T. Anti-enolase1antibodies from a patient with systemic lupus erythematosus accompanied by pulmonary arterial hypertension promote migration of pulmonary artery smooth muscle cells. Immunol Lett 2019; 218:22-29. [PMID: 31866401 DOI: 10.1016/j.imlet.2019.12.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2019] [Revised: 12/10/2019] [Accepted: 12/17/2019] [Indexed: 12/22/2022]
Abstract
OBJECTIVE Pulmonary arterial hypertension (PAH) is an intractable complication in connective tissue diseases, but the pathological mechanisms responsible for progression remain obscure. This study aims to test whether patient IgG possesses biological activity promoting the migration of pulmonary artery smooth muscle cells (PASMCs). METHODS Cell migration was estimated by lamellipodia formation and by utilizing a Boyden chamber method. The specificity of autoantibodies was established by western blotting, ELISA, and immunocytochemistry. The target antigen was investigated by mass spectrometry. RESULTS IgG obtained from a patient with systemic lupus erythematosus (SLE) accompanied by PAH was found to promote lamellipodia formation and migration of PASMCs. The IgG bound to a ∼50 kDa protein expressed on the cell membrane, and in the cytoplasm and nucleus. This molecule was identified as enolase 1. Removal of enolase 1-binding antibodies from the IgG fraction, or treatment of the cells with an enolase inhibitor, significantly suppressed the migration of PASMCs. CONCLUSION Patients with SLE may possess autoantibodies to enolase 1 which stimulate the migration of PASMCs and are likely to play a role in the progression of PAH.
Collapse
Affiliation(s)
- Y Kato
- Department of Immunopathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
| | - T Kasama
- HiPep Laboratories, Kyoto, Japan
| | - M Soejima
- Soka Municipal Hospital, Soka, Japan
| | - T Kubota
- Department of Immunopathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| |
Collapse
|
13
|
Isojima S, Miura Y, Saito M, Yajima N, Miwa Y, Kasama T. Serum anti-Müllerian hormone levels in women with rheumatoid arthritis during tumor necrosis factor-α inhibitor treatment: Exploratory research. Obstet Med 2019; 12:186-189. [PMID: 31853259 DOI: 10.1177/1753495x18820471] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2018] [Accepted: 11/28/2018] [Indexed: 12/19/2022] Open
Abstract
Background We evaluated serum anti-Müllerian hormone in women with rheumatoid arthritis newly introduced to tumor necrosis factor-α inhibitor treatment for 54 weeks to investigate the treatment's effect on ovarian reserve. Methods A total of 12 premenopausal women with rheumatoid arthritis aged 20-50 years were recruited at our division, who had been newly treated with tumor necrosis factor-α inhibitor (infliximab or etanercept) from 1 April 2008 to 31 March 2014. Serial serum anti-Müllerian hormone levels and disease activity scores (DAS28-CRP) were examined at defined periods: start of treatment and 14, 30, and 54 weeks after start of treatment. Results DAS28-CRP scores in 12 women were significantly decreased from a mean of 4.6 (±SD: 0.4) to 2.3 (±0.4) after 54 weeks of treatment (p < 0.001). Serum anti-Müllerian hormone levels and its z scores did not change significantly. Conclusion Treatment with a tumor necrosis factor-α inhibitor did not affect serum anti-Müllerian hormone levels in 12 women with rheumatoid arthritis during 54-week treatment.
Collapse
Affiliation(s)
- Sakiko Isojima
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Yoko Miura
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Mayu Saito
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Nobuyuki Yajima
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Yusuke Miwa
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| |
Collapse
|
14
|
Ikari Y, Isozaki T, Tsubokura Y, Kasama T. Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes. Cells 2019; 8:cells8060561. [PMID: 31181818 PMCID: PMC6627593 DOI: 10.3390/cells8060561] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2019] [Revised: 06/05/2019] [Accepted: 06/07/2019] [Indexed: 12/22/2022] Open
Abstract
Background: This study was performed to examine the effects of the Janus kinase (JAK) inhibitor peficitinib on fibroblast-like synoviocytes (FLS) obtained from patients with rheumatoid arthritis (RA). Methods: To examine the expression of JAK1, JAK2, and JAK3 in RA synovial tissue (ST) and FLS, immunohistochemistry was performed. We investigated the effects of peficitinib on interleukin 6 and IL-6 receptor responses in RA FLS. Phosphorylation of STAT was determined by western blot. To examine the functional analysis of peficitinib, we performed a proliferation and chemotaxis assays with FLS using THP-1 and peripheral blood mononuclear cells (PBMC). The inflammatory mediator expression of FLS was estimated by enzyme-linked immunosorbent assay. Results: JAK1, JAK2, and JAK3 were expressed in RA STs and FLS. Phosphorylation of STAT1, STAT3, and STAT5 in RA FLS was suppressed by peficitinib in a concentration-dependent manner. Peficitinib-treated RA FLS-conditioned medium reduced THP-1 and PBMC migration (p < 0.05) and proliferation of RA FLS (p < 0.05). Peficitinib suppressed the secretion of MCP-1/CCL2 in the RA FLS supernatant (p < 0.05). Conclusion: Peficitinib suppressed the JAK-STAT pathway in RA FLS and also suppressed monocyte chemotaxis and proliferation of FLS through inhibition of inflammatory cytokines.
Collapse
Affiliation(s)
- Yuzo Ikari
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8555, Japan.
| | - Takeo Isozaki
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8555, Japan.
| | - Yumi Tsubokura
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8555, Japan.
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8555, Japan.
| |
Collapse
|
15
|
Nishimi S, Isozaki T, Wakabayashi K, Takeuchi H, Kasama T. A Disintegrin and Metalloprotease 15 is Expressed on Rheumatoid Arthritis Synovial Tissue Endothelial Cells and may Mediate Angiogenesis. Cells 2019; 8:cells8010032. [PMID: 30634456 PMCID: PMC6356746 DOI: 10.3390/cells8010032] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Revised: 01/03/2019] [Accepted: 01/05/2019] [Indexed: 01/03/2023] Open
Abstract
A disintegrin and metalloprotease 15 (ADAM15) is involved in several malignancies. In this study, we investigated the role of ADAM15 in rheumatoid arthritis (RA) angiogenesis. Soluble ADAM15 (s-ADAM15) in serum from RA and normal (NL) subjects was measured using ELISA. To determine membrane-anchored ADAM15 (ADAM15) expression in RA synovial tissues, immunohistochemistry was performed. To examine the role of ADAM15 in angiogenesis, we performed in vitro Matrigel assays and monocyte adhesion assays using human umbilical vein endothelial cells (HUVECs) transfected with ADAM15 siRNA. Finally, to investigate whether angiogenic mediators were affected by ADAM15, cytokines in ADAM15 siRNA-transfected HUVEC-conditioned medium were measured. ADAM15 was significantly higher in RA serum than in NL serum. ADAM15 was also expressed on RAST endothelial cells. ADAM15 siRNA-treated HUVECs had decreased EC tube formation in response to RA synovial fluids compared with non-treated HUVECs. The adhesion index of ADAM15 siRNA-transfected HUVECs was significantly lower than the adhesion index of control siRNA-transfected HUVECs. ENA-78/CXCL5 and ICAM-1 were decreased in tumor necrosis factor (TNF)-α-stimulated ADAM15 siRNA-transfected HUVEC-conditioned medium compared with TNF-α-stimulated control siRNA-transfected HUVEC-conditioned medium. These data show that ADAM15 plays a role in RA angiogenesis, suggesting that ADAM15 might be a potential target in inflammatory diseases such as RA.
Collapse
Affiliation(s)
- Shinichiro Nishimi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8555, Japan.
| | - Takeo Isozaki
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8555, Japan.
| | - Kuninobu Wakabayashi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8555, Japan.
| | - Hiroko Takeuchi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8555, Japan.
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8555, Japan.
| |
Collapse
|
16
|
Yogo N, Hase T, Kasama T, Hatta T, OZAWA N, Sato M, Kaji N, Tokeshi M, Baba Y, Hasegawa Y. Development of the immuno-wall device for rapid detection of ALK and ROS1 fusions in lung cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy441.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
17
|
Ishii S, Isozaki T, Furuya H, Takeuchi H, Tsubokura Y, Inagaki K, Kasama T. ADAM-17 is expressed on rheumatoid arthritis fibroblast-like synoviocytes and regulates proinflammatory mediator expression and monocyte adhesion. Arthritis Res Ther 2018; 20:159. [PMID: 30071898 PMCID: PMC6090907 DOI: 10.1186/s13075-018-1657-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Accepted: 06/29/2018] [Indexed: 12/11/2022] Open
Abstract
Background To examine the expression of ADAM-17 in rheumatoid arthritis (RA) biological fluids and the role it plays in monocyte adhesion to RA fibroblast-like synoviocytes (FLSs). Methods ADAM-17 expression was measured by enzyme-linked immunosorbent assays (ELISAs) in serum from normal (NL) subjects, osteoarthritis (OA) patients, and RA patients. We also analyzed the correlation between ADAM-17 and disease activity score 28 (DAS28) in RA. To determine expression of ADAM-17 in RA synovial tissues (STs) and RA FLS, we performed immunofluorescence analyses. To determine the role of ADAM-17 in RA, we transfected RA FLSs with small interfering RNA (siRNA) against ADAM-17. THP-1 adhesion to ADAM-17 siRNA-transfected RA FLSs was measured. Finally, adhesion molecules on ADAM-17 siRNA-transfected RA FLSs were measured using cell surface ELISAs. Results ADAM-17 in RA serum was significantly higher than that in NL and OA serum and correlated with DAS28. ADAM-17 in RA synovial fluids was higher than that in OA synovial fluids. ADAM-17 was expressed on RA cells lining STs and RA FLSs. THP-1 adhesion to ADAM-17 siRNA-transfected RA FLSs was decreased compared with that to control siRNA-transfected RA FLSs. ICAM-1 on TNF-α-stimulated ADAM-17 siRNA-transfected RA FLSs was significantly decreased compared with that on control siRNA-transfected RA FLSs. Conclusions These data indicate that ADAM-17 is expressed on RA STs and plays a role in RA inflammation by regulating monocyte adhesion to RA FLSs. ADAM-17 might be an important inflammatory mediator in inflammatory diseases such as RA.
Collapse
Affiliation(s)
- Sho Ishii
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Takeo Isozaki
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan.
| | - Hidekazu Furuya
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Hiroko Takeuchi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Yumi Tsubokura
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Katsunori Inagaki
- Department of Orthopedic Surgery, Showa University School of Medicine, Tokyo, Japan
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| |
Collapse
|
18
|
Miwa Y, Furuya H, Yanai R, Kasama T, Sanada K. Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression? Eur J Rheumatol 2018; 5:22-26. [PMID: 29657870 DOI: 10.5152/eurjrheum.2018.17021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2017] [Accepted: 07/12/2017] [Indexed: 11/22/2022] Open
Abstract
Objective The objective of this study was to investigate the factors associated with depression, including serum oxytocin (OXT) levels, disease activity, activities of daily living (ADL), and quality of life (QOL), and their effects on rheumatoid arthritis (RA). Methods This study included 42 RA patients who received treatment with a biological agent. We measured the following variables before and after 6 months of treatment: baseline characteristics, including age, sex, disease duration, smoking, and body mass index (BMI); prednisolone and methotrexate dose; serum level of matrix metalloproteinase-3 (MMP-3); erythrocyte sedimentation rate (ESR); and C-reactive protein (CRP) level. The disease activity of RA was assessed using the Simplified Disease Activity Index (SDAI); depression was assessed using the Hamilton Depression Rating Scale (HAM-D); ADL was assessed using the Health Assessment Questionnaire; and QOL was assessed using the Short Form (SF)-36. Serum OXT levels were determined using enzyme-linked immunosorbent assay. Results The HAM-D score significantly correlated with the SDAI, and the mental component summary (MCS) score of SF-36. However, the serum OXT levels did not correlate with the HAM-D score. Regression analysis using the HAM-D score as the objective variable identified female sex, smoking, BMI, and all the three component scores of SF-36, but not serum OXT levels, as significant factors. Comparisons between before and after treatment showed that the HAM-D score improved from 5 to 1.5; however, the serum OXT levels did not change. Conclusion The variables of female sex, smoking, BMI, and QOL correlated with depression complicated with RA. However, serum OXT levels did not correlate directly.
Collapse
Affiliation(s)
- Yusuke Miwa
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Hidekazu Furuya
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Ryo Yanai
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Kenji Sanada
- Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan
| |
Collapse
|
19
|
Nishimi A, Isozaki T, Nishimi S, Ishii S, Tokunaga T, Furuya H, Wakabayashi K, Kasama T. Correction to: ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease. Clin Rheumatol 2018. [DOI: 10.1007/s10067-018-4050-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
20
|
Miwa Y, Ikari Y, Hosonuma M, Hatano M, Hayashi T, Kasama T, Sanada K. A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment. Eur J Rheumatol 2018; 5:111-114. [PMID: 30185359 DOI: 10.5152/eurjrheum.2018.17147] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2017] [Accepted: 10/01/2017] [Indexed: 12/11/2022] Open
Abstract
OBJECTIVE To investigate the relationship between baseline factors and depression remission after a 6-month biological disease-modifying antirheumatic drugs (bDMARDs) treatment in rheumatoid arthritis (RA) patients. METHODS The study was conducted in 152 RA patients treated with bDMARDs. The following patient's characteristics were studied: gender, age, disease duration, baseline prednisolone dosage, and serum matrix metalloproteinase3 (MMP3) levels. For assessment, we used the simple disease activity index (SDAI) for RA disease activity, Health Assessment Questionnaire Disability Index (HAQ-DI) for activities of daily living (ADL), Short Form-36 for nonspecific health-related quality of life (QOL), and Hamilton Depression Rating Scale (HAM-D) scores for the depression status. Depressed remission was clarified using HAM-D ≤7 after 6 months of treatment. The patients were divided into two groups according to the presence or absence of depression, and a retrospective study was conducted. RESULTS Based on binominal logistic analyses, RA patients' with depression remission (n=124) compared to those without depression remission (n=28) had a younger age (p=0.0045, odd ratio: 0.94, 95% confidence interval [CI]:0.8-0.98), female sex (p=0.021, odd ratio:0.21, 95% CI:0.054-0.79), and lower HAM-D scores (p=0.0073, odd ratio:0.85, 95% CI:0.76-0.96) CONCLUSION: It was proposed that RA patients who are females, younger in age, and have lower depressed scores at baseline can achieve a depression remission status with the bDMARDs treatment.
Collapse
Affiliation(s)
- Yusuke Miwa
- Department of Rheumatology, Showa University School of Medicine, Tokyo, Japan
| | - Yuzo Ikari
- Department of Rheumatology, Showa University School of Medicine, Tokyo, Japan
| | - Masahiro Hosonuma
- Department of Rheumatology, Showa University School of Medicine, Tokyo, Japan
| | - Mika Hatano
- Department of Rheumatology, Showa University School of Medicine, Tokyo, Japan
| | - Tomoki Hayashi
- Department of Rheumatology, Showa University School of Medicine, Tokyo, Japan
| | - Tsuyoshi Kasama
- Department of Rheumatology, Showa University School of Medicine, Tokyo, Japan
| | - Kenji Sanada
- Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan
| |
Collapse
|
21
|
Miwa Y, Saito M, Furuya H, Yanai R, Kasama T. Predictor of the Simplified Disease Activity Index 50 (SDAI 50) at Month 3 of bDMARD Treatment in Patients with Long-Established Rheumatoid Arthritis. Open Rheumatol J 2018; 11:106-112. [PMID: 29290847 PMCID: PMC5737026 DOI: 10.2174/1874312901711010106] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2017] [Revised: 06/21/2017] [Accepted: 09/12/2017] [Indexed: 01/22/2023] Open
Abstract
Objectives: The Simplified Disease Activity Index (SDAI) 50 has good agreement with European League Against Rheumatism (EULAR) response measures for early Rheumatoid Arthritis (RA). There have been reports on early RA, but not on long-established RA. In this study, we analysed the relationships between various baseline factors and SDAI 50 after three months of treatment with biological disease-modifying antirheumatic drugs (bDMARDs) to determine the prognostic factors for long-established RA. Methods: Subjects were 260 RA patients who had been treated with bDMARDs for 3 months. The following characteristics were investigated: Patient backgrounds, the erythrocyte sedimentation rate (ESR), C-reactive protein and serum matrix metalloproteinase-3 levels, SDAI scores, and health assessment questionnaire disability index and short form-36 scores. As a primary outcome index, the SDAI response was defined as a 50% reduction in the SDAI score between baseline and 3 months (SDAI 50). Results: Baseline values of disease duration (odds ratio: 0.942, 95% CI: 0.902-0.984), smoking history (odds ratio: 2.272, 1.064-4.850), 28-tender joint count (odds ratio: 0.899, 0.827-0.977), evaluator's global assessment (odds ratio: 1.029, 1.012-1.047) and ESR (odds ratio: 1.015, 1.001-1.030) were determined to be significant factors based on logistic regression analysis. Conclusion: Our study demonstrated that RA patients with shorter disease duration, no smoking, and higher RA disease activity are more likely to achieve SDAI 50 through bDMARD treatment.
Collapse
Affiliation(s)
- Yusuke Miwa
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Mayu Saito
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Hidekazu Furuya
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Ryo Yanai
- Division of Rheumatology, Department of Medicine, Showa University Koto-Toyosu Hospital, Tokyo, Japan
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University Koto-Toyosu Hospital, Tokyo, Japan
| |
Collapse
|
22
|
Abstract
Objective To investigate the factors associated with depression, including the serum oxytocin (OXT) levels, disease activity, activities of daily living (ADLs) and quality of life (QOL), and their effects on rheumatoid arthritis (RA). Methods This study included 42-RA-patients. We measured the following variables before and after 6 months of treatment with biological disease-modifying antirheumatic drugs (bDMARDs): the baseline characteristics (including age, sex, disease duration, smoking, and body mass index), the doses of prednisolone and methotrexate, the serum level of matrix metalloprotease-3, the erythrocyte sedimentation rate and the C-reactive protein level. The disease activity of RA was assessed using the Simplified Disease Activity Index (SDAI), depression was assessed using the Hamilton Depression Rating Scale (HAM-D), the ADLs were assessed using the Health Assessment Questionnaire disability index and the QOL was assessed using the Short Form (SF)-36. The serum OXT levels were determined using an enzyme-linked immunosorbent assay. Results The HAM-D score was significantly correlated with the SDAI, and the mental component summary score of the SF-36. However, the serum OXT levels were not correlated with the HAM-D score. The serum OXT levels before and after bDMARDs treatment did not differ to a statistically significant extent, regardless of the presence of depression. Although the differences in the serum levels of OXT were observed prior to the initiation of treatment, there was no gender difference after treatment. Conclusion Although RA complicated by depression may be related to the following high disease activity, a poor QOL and poor ADLs, the serum OXT levels were not directly correlated.
Collapse
Affiliation(s)
- Yusuke Miwa
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Hidekazu Furuya
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Ryo Yanai
- Division of Rheumatology, Department of Medicine, Showa University Koto-Toyosu Hospital, Japan
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University Koto-Toyosu Hospital, Japan
| | - Kenji Sanada
- Department of Psychiatry, Showa University School of Medicine, Japan
| |
Collapse
|
23
|
Yogo N, Hase T, Kasama T, Ozawa N, Sato M, Kaji N, Tokeshi M, Baba Y, Hasegawa Y. Development of the immuno-wall device for rapid, low-cost detection of EGFR mutations in tumor samples from patients with lung cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx672.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Dastjerdi MHT, Fiordaliso EM, Leshchenko ED, Akhtari-Zavareh A, Kasama T, Aagesen M, Dubrovskii VG, LaPierre RR. Three-fold Symmetric Doping Mechanism in GaAs Nanowires. Nano Lett 2017; 17:5875-5882. [PMID: 28903563 DOI: 10.1021/acs.nanolett.7b00794] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
A new dopant incorporation mechanism in Ga-assisted GaAs nanowires grown by molecular beam epitaxy is reported. Off-axis electron holography revealed that p-type Be dopants introduced in situ during molecular beam epitaxy growth of the nanowires were distributed inhomogeneously in the nanowire cross-section, perpendicular to the growth direction. The active dopants showed a remarkable azimuthal distribution along the (111)B flat top of the nanowires, which is attributed to preferred incorporation along 3-fold symmetric truncated facets under the Ga droplet. A diffusion model is presented to explain the unique radial and azimuthal variation of the active dopants in the GaAs nanowires.
Collapse
Affiliation(s)
- M H T Dastjerdi
- Department of Engineering Physics, Centre for Emerging Device Technologies, McMaster University , Hamilton, Ontario Canada , L8S 4L7
| | - E M Fiordaliso
- Center for Electron Nanoscopy, Technical University of Denmark , DK-2800 Kongens Lyngby, Denmark
| | - E D Leshchenko
- ITMO University , Kronverkskiy pr. 49, 197101 St. Petersburg, Russia
| | - A Akhtari-Zavareh
- Department of Engineering Physics, Centre for Emerging Device Technologies, McMaster University , Hamilton, Ontario Canada , L8S 4L7
| | - T Kasama
- Center for Electron Nanoscopy, Technical University of Denmark , DK-2800 Kongens Lyngby, Denmark
| | - M Aagesen
- Gasp Solar ApS, Gregersensvej 7, DK-2630 Taastrup, Denmark
- Center for Quantum Devices, Niels Bohr Institute, University of Copenhagen , Universitetsparken 5, 2100 Copenhagen, Denmark
| | - V G Dubrovskii
- ITMO University , Kronverkskiy pr. 49, 197101 St. Petersburg, Russia
- St. Petersburg Academic University , Khlopina 8/3, 194021 St. Petersburg, Russia
- Ioffe Physical Technical Institute of the Russian Academy of Sciences , Politekhnicheskaya 26, 194021 St. Petersburg, Russia
| | - R R LaPierre
- Department of Engineering Physics, Centre for Emerging Device Technologies, McMaster University , Hamilton, Ontario Canada , L8S 4L7
- ITMO University , Kronverkskiy pr. 49, 197101 St. Petersburg, Russia
| |
Collapse
|
25
|
Miwa Y, Saito M, Furuya H, Yanai R, Ikari Y, Hayashi T, Kasama T, Toyoshima Y, Inagaki K. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment. Intern Med 2017; 56:2271-2275. [PMID: 28794381 PMCID: PMC5635297 DOI: 10.2169/internalmedicine.8723-16] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Objectives We aimed to identify the factors that predict the likelihood of remission based on a health assessment questionnaire (HAQ) in rheumatoid arthritis (RA) patients who received non-tumor necrosis factor (TNF) biologics for six months before they commenced definitive treatment. Methods The subjects consisted of 97 RA patients treated with tocilizumab or abatacept for 6 months. The following characteristics were investigated: age, gender, body mass index, steroid and methotrexate dosage, serum matrix metalloproteinase-3 levels, simplified disease activity index (SDAI) score, HAQ score (for assessing the activities of daily living [ADL]) and the short form (SF)-36 score (for assessing the quality of life [QOL]). Remission based on the HAQ score is defined as HAQ ≤0.5 after 6 months of treatment. The subjects were divided into two groups: patients with HAQ score ≤0.5 and HAQ score >0.5, and a retrospective study was conducted. Results The group of RA patients who entered remission based on the HAQ (53 patients) had a lower SDAI than the patients who did not enter remission (44 patients), and the RA patients had a lower tender joint count (TJC) and HAQ scores and a lower physician's global assessment (PGA) than those who did not enter remission. The physical component summary score (PCS) and role/social component summary score (RCS) of the SF-36 summary score were higher in the remission patients than in those without. Before the start of the treatment, the HAQ score, patients' global assessment (PtGA) and PCS and mental component summary score (MCS) of the SF-36 were determined based on a logistic regression analysis. Conclusion Our findings suggest that RA patients with lower HAQ scores and PtGA and higher PCS and MCS of the SF-36 at baseline are more likely to achieve HAQ remission with non-TNF biologic treatment than others.
Collapse
Affiliation(s)
- Yusuke Miwa
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Mayu Saito
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Hidekazu Furuya
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Ryo Yanai
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Yuzo Ikari
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Tomoki Hayashi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Yoichi Toyoshima
- Department of Orthopedics, Showa University School of Medicine, Japan
| | - Katsunori Inagaki
- Department of Orthopedics, Showa University School of Medicine, Japan
| |
Collapse
|
26
|
Miwa Y, Takahashi R, Ikari Y, Maeoka A, Nishimi S, Oguro N, Hayashi T, Hatano M, Isojima S, Yanai R, Kasama T, Toyoshima Y, Inagaki K, Sanada K. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment. Intern Med 2017; 56:903-906. [PMID: 28420837 PMCID: PMC5465405 DOI: 10.2169/internalmedicine.56.8039] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Objective Although previous studies have reported the prognostic factors for functional remission, no reports have cited the predictive factors. Our aim was to study the predictive factors for functional remission, which is a treatment goal in rheumatoid arthritis (RA), after receiving biological disease-modifying antirheumatic drugs (bDMARDs) treatment for six months. Methods The study consisted of 333 RA patients treated with bDMARDs for six months. The following patient characteristics were investigated: age, gender, disease duration, type of bDMARDs, baseline steroid and methotrexate dosage, and levels of serum rheumatoid factor, matrix metalloprotease, anti-cyclic citrullinated peptides antibody, tumor necrosis factor-α, and interleukin-6. In our evaluation, we used the Simplified Disease Activity Index (SDAI) for RA disease activity, health assessment questionnaire disability index (HAQ-DI) for activity of daily living, Short Form (SF)-36 for quality of life, and Hamilton Depression Rating Scale (HAM-D) or Self-rating Depression Scale (SDS) to determine the patients' depression status. The subjects were divided into two groups: patients with HAQ-DI≤0.5 and HAQ-DI>0.5 at 6 months. Results A univariate analysis comparing a group of RA patients without functional remission (n=68) showed that the patients with functional remission (n=164) had the following in common compared with those without remission: younger age, shorter disease duration, lower baseline steroid dosage, lower SDAI, lower HAQ-DI, higher SF-36, and lower HAM-D. Only lower HAQ-DI scores and "mental health" score on the SF-36 were detected using a logistic regression analysis. Conclusion These findings suggested that RA patients with lower HAQ-DI and lower depression scores at baseline were more likely to achieve functional remission using bDMARDs treatment than those without these variables.
Collapse
Affiliation(s)
- Yusuke Miwa
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Ryo Takahashi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Yuzo Ikari
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Airi Maeoka
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Shinichiro Nishimi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Nao Oguro
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Tomoki Hayashi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Mika Hatano
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Sakiko Isojima
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Ryo Yanai
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Yoichi Toyoshima
- Department of Orthopedics, Showa University School of Medicine, Japan
| | - Katsunori Inagaki
- Department of Orthopedics, Showa University School of Medicine, Japan
| | - Kenji Sanada
- Department of Psychiatry, Showa University School of Medicine, Japan
| |
Collapse
|
27
|
Isozaki T, Nishimi S, Nishimi A, Saito M, Miwa Y, Toyoshima Y, Inagaki K, Kasama T. A disintegrin and metalloproteinase (ADAM)-10 as a predictive factor for tocilizumab effectiveness in rheumatoid arthritis. Mod Rheumatol 2016; 27:782-786. [PMID: 27846745 DOI: 10.1080/14397595.2016.1256025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
OBJECTIVES A disintegrin and metalloproteinase (ADAM)-10 is expressed in rheumatoid arthritis (RA). In this study, we focused on ADAM-10 as a predictive factor for the treatment with biologics in RA. METHODS The levels of ADAM-10 and fractalkine/CX3CL1 in RA and healthy controls serum were measured using enzyme-linked immunosorbent assays. Fifteen patients were treated with adalimumab (ADA), and 20 patients were treated with tocilizumab (TCZ). RESULTS ADAM-10 positively correlated with fractalkine/CX3CL1 in the sera of RA patients and was presented at a significantly higher level compared to that in normal serum (487 ± 80 pg/ml and 85 ± 33 pg/ml, respectively, p < 0.05). ADAM-10 highly correlates with fractalkine/CX3CL1 in the sera of RA patients. The level of ADAM-10 decreased after the treatment with TCZ but not with ADA. In addition, we found that the level of ADAM-10 in TCZ responders was significantly higher than that of the TCZ nonresponders at 24 weeks (619 ± 134 pg/ml and 109 ± 25 pg/ml, respectively). Multiple regression analysis showed that ADAM-10 was only identified as independent predictive variable for the improvement of DAS28 (ESR) at 24 weeks. CONCLUSIONS ADAM-10 may be a predictor of the effectiveness of TCZ in treating RA.
Collapse
Affiliation(s)
- Takeo Isozaki
- a Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan and
| | - Shinichiro Nishimi
- a Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan and
| | - Airi Nishimi
- a Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan and
| | - Mayu Saito
- a Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan and
| | - Yusuke Miwa
- a Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan and
| | - Yoichi Toyoshima
- b Department of Orthopedics , Showa University School of Medicine , Tokyo , Japan
| | - Katsunori Inagaki
- b Department of Orthopedics , Showa University School of Medicine , Tokyo , Japan
| | - Tsuyoshi Kasama
- a Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan and
| |
Collapse
|
28
|
Miwa Y, Hatano M, Nishimi A, Nishimi S, Hayashi T, Yanai R, Furuya H, Umemura M, Kasama T, Hosaka M, Sanada K. AB0296 Clinical Characteristics of Rheumatoid Arthritis Patients Achieving No Depression with 6 Months of Biologic Treatment. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Miwa Y, Takahashi R, Isojima S, Saito M, Miura Y, Ishii S, Ikari Y, Tokunaga T, Kasama T, Toyoshima Y, Inagaki K. FRI0153 Relationship between Serum Oxytocin Levels and Disease Activity, Depressive State, ADL, and QOL in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Kasama T, Isozaki T, Takahashi R, Miwa Y. Clinical effects of tocilizumab on cytokines and immunological factors in patients with rheumatoid arthritis. Int Immunopharmacol 2016; 35:301-306. [PMID: 27085681 DOI: 10.1016/j.intimp.2016.03.016] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Revised: 03/02/2016] [Accepted: 03/14/2016] [Indexed: 12/15/2022]
Abstract
Interleukin (IL)-6 is one of the crucial proinflammatory cytokines. The dysregulation of IL-6 plays a pivotal role in rheumatoid arthritis (RA) and is involved in several of the common clinical manifestations associated with active RA. Recent therapies targeting IL-6 and tumor necrosis factor (TNF) have resulted in clinical improvements in signs and symptoms, disability and quality of life in patients with early and long-standing RA. Because it has been demonstrated that cytokines and inflammatory/immunological factors appear to be important and sensitive mediators in RA patients treated with tocilizumab and with anti-TNF biologics, it is important to investigate whether tocilizumab administration has any effect(s) on the profiles of cytokines and inflammatory/immunological factors and whether these changes correlate with the clinical improvement in RA disease activity. In this review, we discuss the effects on cytokine regulation and the differentiation of immune cells, especially T cells, after tocilizumab therapy in patients with RA.
Collapse
Affiliation(s)
- Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan; Division of Rheumatology, Showa University Kototoyosu Hospital, Tokyo, Japan.
| | - Takeo Isozaki
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Ryo Takahashi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Yusuke Miwa
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| |
Collapse
|
31
|
Kasama T, Maeoka A, Oguro N. Clinical Features of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Other Connective Tissue Diseases. Clin Med Insights Arthritis Musculoskelet Disord 2016; 9:1-8. [PMID: 26819561 PMCID: PMC4718090 DOI: 10.4137/cmamd.s37477] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Revised: 12/17/2015] [Accepted: 12/17/2015] [Indexed: 12/13/2022]
Abstract
Systemic lupus erythematosus (SLE) and related disorders are chronic inflammatory diseases characterized by abnormalities and, in some cases, even complete failure of immune responses as the underlying pathology. Although almost all connective tissue diseases and related disorders can be complicated by various neuropsychiatric syndromes, SLE is a typical connective tissue disease that can cause neurological and psychiatric syndromes. In this review, neuropsychiatric syndromes complicating connective tissue diseases, especially SLE are outlined, and pathological and other conditions that should be considered in the differential diagnosis are also discussed.
Collapse
Affiliation(s)
- Tsuyoshi Kasama
- Division of Rheumatology, Showa University Koto Toyosu Hospital, Tokyo, Japan
| | - Airi Maeoka
- Division of Rheumatology, Showa University Koto Toyosu Hospital, Tokyo, Japan
| | - Nao Oguro
- Division of Rheumatology, Showa University Koto Toyosu Hospital, Tokyo, Japan
| |
Collapse
|
32
|
Miwa Y, Isojima S, Saito M, Ikari Y, Kobuna M, Hayashi T, Takahashi R, Kasama T, Hosaka M, Sanada K. Comparative Study of Infliximab Therapy and Methotrexate Monotherapy to Improve the Clinical Effect in Rheumatoid Arthritis Patients. Intern Med 2016; 55:2581-5. [PMID: 27629950 DOI: 10.2169/internalmedicine.55.6872] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Objective We examined whether infliximab (IFX) therapy was more effective than methotrexate (MTX) monotherapy to achieve an improvement in depressive states in Rheumatoid Arthritis (RA) patients. Methods We examined 152 RA patients (72 IFX patients and 80 MTX patients). We conducted an open-label cohort study to evaluate the disease activity of RA (Simplified Disease Activity Index; SDAI), depressive states (Hamilton Rating Scale for Depression; HAM-D), Activity of Daily Living (ADL) (modified Health Assessment Questionnaire; mHAQ) and Quality of Life (QOL) [Short Form (SF)-36] in patients before and 6 months after receiving therapy. The HAM-D, SDAI, mHAQ and SF-36 scores after 6 months of therapy were measured as the outcomes. Results We analyzed 60 IFX patients and 53 MTX patients. The HAM-D scores significantly improved in both groups (p<0.001), but there was no significant difference in the effectiveness between the IFX and MTX therapies (p=0.792). The SDAI scores significantly improved in both groups after therapy (p<0.001), and IFX therapy was more effective than MTX therapy (p=0.004). The mHAQ and HAM-D scores also improved significantly in both groups after therapy (p<0.001), but no significant difference in the effectiveness between the IFX and MTX therapies was observed (p=0.272, 0.792). The scores of all 8 items of the SF-36 improved in both groups after therapy, but IFX therapy was more effective than MTX therapy in only 4 of the 8 items (p<0.05). Conclusion Both IFX and MTX therapy improved the clinical efficacy, ADL, QOL and depressive states. However, no significant differences regarding an improvement in the depressive states and ADL were observed between IFX therapy and MTX monotherapy.
Collapse
Affiliation(s)
- Yusuke Miwa
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Yamanaka H, Nagaoka S, Lee SK, Bae SC, Kasama T, Kobayashi H, Nishioka Y, Ueki Y, Seto Y, Nishinarita M, Tamura N, Kimura N, Saito K, Tomita T, Nawata Y, Suzuki S, Ishigatsubo Y, Munakata Y, Makino Y, Inoue E, Tanaka Y, Takeuchi T. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Mod Rheumatol 2015; 26:651-61. [PMID: 26698929 DOI: 10.3109/14397595.2015.1123349] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
OBJECTIVES To investigate the efficacy and safety of etanercept (ETN) in patients with rheumatoid arthritis (RA) with moderate disease activity and the possibility to discontinue ETN after achieving remission. METHODS Multicenter, randomized, and open-label study was conducted in Japan and Korea. RA patients (disease duration <5 years) with moderate disease activity despite methotrexate (MTX) treatment were allocated to either MTX or ETN + MTX (Period 1) for 12 months. Patients who achieved sustained remission defined as DAS28 < 2.6 at both 6 and 12 months in the ETN + MTX group, were randomized to either continue or discontinue ETN for 12 months (Period 2). RESULTS A total of 222 patients were enrolled in Period 1 and clinical remission was achieved in 106/157 (67.5%) and 5/28 (17.9%) patients in the ETN + MTX and MTX groups, respectively. In Period 2, sixty-seven patients were randomized and finally 28/32 (87.5%) and 15/28 (53.6%) patients who continued or discontinued ETN maintained clinical remission. Baseline disease activity and the presence of comorbid diseases influenced the maintenance of remission after ETN discontinuation. CONCLUSIONS ETN + MTX was efficient for RA patients with moderate disease activity into remission. After achieving sustained remission, a half of the patients who discontinued ETN could maintain remission for 1 year.
Collapse
Affiliation(s)
- Hisashi Yamanaka
- a Institute of Rheumatology, Tokyo Women's Medical University , Japan
| | - Shouhei Nagaoka
- b Internal Department of Rheumatology , Yokohama Minami Kyosai Hospital , Japan
| | - Soo-Kon Lee
- c Department of Rheumatology , Yonsei University College of Medicine , Korea
| | - Sang-Cheol Bae
- d Hanyang University Hospital for Rheumatic Diseases , Korea
| | - Tsuyoshi Kasama
- e Department of Rheumatology , Showa University Hospital , Japan
| | - Hitomi Kobayashi
- f Department of Internal Medicine , Itabashi Chuo Medical Center , Japan
| | - Yuichi Nishioka
- g Department of Rheumatism , Nishioka Clinic for Rheumatic Diseases and Allergic Diseases , Japan
| | - Yukitaka Ueki
- h Rheumatic Diseases Center , Sasebo Chuo Hospital , Japan
| | - Yohei Seto
- a Institute of Rheumatology, Tokyo Women's Medical University , Japan
| | - Makoto Nishinarita
- i Department of Internal Medicine and Rheumatology , Nishinarita Clinic , Japan
| | - Naoto Tamura
- j Department of Internal Medicine and Rheumatology , Juntendo University Faculty of Medicine , Japan
| | - Noriko Kimura
- k Division of Rheumatology , Department of Internal Medicine Keio University School of Medicine , Japan
| | - Kazuyoshi Saito
- l The 1st Department of Internal Medicine , School of Medicine University of Occupational & Environmental Health , Japan
| | - Tetsuya Tomita
- m Department of Orthopedic Surgery , Osaka University Hospital , Japan
| | - Yasushi Nawata
- n Center for Rheumatic Diseases , Chibaken Saiseikai Narashino Hospital , Japan
| | - Sadahiro Suzuki
- o Department of Connecting Tissue Disease , Shinonoi General Hospital , Japan
| | - Yoshiaki Ishigatsubo
- p Rheumatology, Hematology, Infectious Diseases , Yokohama City University Hospital , Japan
| | | | - Yuichi Makino
- r The 2nd Department of Internal Medicine , Asahikawa Medical University Hospital , Japan , and
| | - Eisuke Inoue
- s Division of Biostatistics , National Center for Child Health and Development , Japan
| | - Yoshiya Tanaka
- l The 1st Department of Internal Medicine , School of Medicine University of Occupational & Environmental Health , Japan
| | - Tsutomu Takeuchi
- k Division of Rheumatology , Department of Internal Medicine Keio University School of Medicine , Japan
| | | |
Collapse
|
34
|
Isozaki T, Ishii S, Nishimi S, Nishimi A, Oguro N, Seki S, Miura Y, Miwa Y, Oh K, Toyoshima Y, Nakamura M, Inagaki K, Kasama T. A disintegrin and metalloprotease-10 is correlated with disease activity and mediates monocyte migration and adhesion in rheumatoid arthritis. Transl Res 2015; 166:244-53. [PMID: 25796462 DOI: 10.1016/j.trsl.2015.02.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/08/2014] [Revised: 02/24/2015] [Accepted: 02/26/2015] [Indexed: 10/23/2022]
Abstract
A disintegrin and metalloproteases (ADAMs) are a family of proteins that have been reported to be involved in several inflammatory conditions. We examined the secretion of ADAM-10 in biological fluids from patients with rheumatoid arthritis (RA) and the role it plays in monocyte migration. ADAM-10 levels were measured using enzyme-linked immunosorbent assays and immunofluorescence. To examine the role of ADAM-10 in RA synovial fluids (SFs), we studied THP-1 (human acute monocyte leukemia cell line) and monocyte chemotaxis. To determine whether ADAM-10 plays a role in cell proliferation in the RA synovium, we assayed the proliferation of ADAM-10 small interfering RNA (siRNA)-transfected RA fibroblast-like synoviocytes (FLSs). The ADAM-10 level in RA serum was significantly higher than that in normal serum and was correlated with a disease activity score of 28. ADAM-10-depleted RA SFs showed a decrease in THP-1 and monocyte migratory activity compared with that of sham-depleted controls. ADAM-10 siRNA inhibited monocyte adhesion to RA FLSs. Finally, blocking ADAM-10 secretion in RA FLSs resulted in decreased production of fractalkine/CX3CL1 and vascular endothelial cell growth factor. These data indicate that ADAM-10 plays a role in monocyte migration in RA and suggest that targeting ADAM-10 may provide a method of decreasing inflammation and potentially treating other inflammatory diseases.
Collapse
Affiliation(s)
- Takeo Isozaki
- Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan.
| | - Sho Ishii
- Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Shinichiro Nishimi
- Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Airi Nishimi
- Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Nao Oguro
- Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Shinya Seki
- Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Yoko Miura
- Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Yusuke Miwa
- Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Koei Oh
- Department of Orthopedics, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Yoichiro Toyoshima
- Department of Orthopedics, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Masanori Nakamura
- Department of Orthopedics, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Katsunori Inagaki
- Department of Orthopedics, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| | - Tsuyoshi Kasama
- Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan
| |
Collapse
|
35
|
Tokunaga T, Miwa Y, Nishimi A, Nishimi S, Saito M, Oguro N, Miura Y, Ishii S, Takahashi R, Kasama T, Sanada K. Sex Differences in the Effects of a Biological Drug for Rheumatoid Arthritis on Depressive State. Open Rheumatol J 2015; 9:51-6. [PMID: 26312106 PMCID: PMC4541463 DOI: 10.2174/1874312901409010051] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2015] [Revised: 05/11/2015] [Accepted: 05/18/2015] [Indexed: 11/22/2022] Open
Abstract
Objective : Sex-specific medicine has attracted attention in recent years, but no report on rheumatoid arthritis (RA) has examined sex differences in the effectiveness of biologics on activities of daily living (ADL), quality of life (QOL), or depressive state. Methods : The study subjects were 161 RA patients (female: 138; male: 23) attending regular doctor visits at our hospital. We compared the changes in disease activity, which was evaluated using the simplified disease activity index (SDAI), ADL (using the modified health assessment questionnaire; mHAQ), QOL (using short form-36; SF-36), and the Hamilton Depression Rating Scale (HAM-D) for RA patients between each sex over a six-month observation period while administering biologic treatment. Results : The female patients reported significant improvements in the following metrics: SDAI: from 22.1 ± 11.9 to 8.9 ± 7.8 (p < 0.001); mHAQ: from 0.46 ± 0.50 to 0.32 ± 0.45 (p < 0.001); and HAM-D: from 6.2 ± 4.8 to 3.8 ± 4.1 (p < 0.001). Moreover, all eight items of the SF-36 were significantly improved (p < 0.01). In contrast, the male patients improved on the SDAI (from 27.9 ± 11.7 to 12.7 ± 8.6 (p < 0.001)), but we did not observe significant improvements in the mHAQ or HAM-D scores or in any items on the SF-36. Conclusion : Both male and female patients with RA improved when using a biological drug. Sex differences in the improvement of depressive state were observed.
Collapse
Affiliation(s)
- Takahiro Tokunaga
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Yusuke Miwa
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Airi Nishimi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Shinichiro Nishimi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Mayu Saito
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Nao Oguro
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Yoko Miura
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Sho Ishii
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Ryo Takahashi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| | - Kenji Sanada
- Department of Psychiatry, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan
| |
Collapse
|
36
|
Miwa Y, Takahashi R, Yajima N, Wakabayashi K, Tokunaga T, Ishii S, Nishimi A, Kasama T, Oh K, Toyoshima Y, Inagaki K. AB0329 A Study on Characteristics of Rheumatoid Arthritis Patients Achieving HAQ Remission with 6 Months of Biologic Treatment. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
37
|
Miwa Y, Takahashi R, Isojima S, Isozaki T, Saito M, Oguro N, Nishimi S, Kasama T, Oh K, Toyoshima Y, Inagaki K. AB0328 A Study on Characteristics of Rheumatoid Arthritis Patients Achieving Clinical Remission After 6 Months of Treatment with Biologic Agents. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
Yanai R, Miwa Y, Kasama T, Yajima N, Isozaki T, Wakabayashi K, Takahashi R, Isojima S, Furuya H, Saito M. SAT0085 Study of Prognostic Factors Associated with Death from Pneumocystis Pneumonia Complicated by Collagen Diseases. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
39
|
Miwa Y, Takahashi R, Yanai R, Furuya H, Umemura M, Miura Y, Kasama T, Oh K, Toyoshima Y, Inagaki K, Hosaka M. AB0406 A Study on Characteristics of Rheumatoid Arthritis Patients Achieving no Depression with 6 Months of Biologic Treatment. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
40
|
Ishii S, Miwa Y, Otsuka K, Nishimi S, Nishimi A, Saito M, Miura Y, Oguro N, Tokunaga T, Takahashi R, Kasama T. Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study. Lupus Sci Med 2015; 2:e000091. [PMID: 26056606 PMCID: PMC4453506 DOI: 10.1136/lupus-2015-000091] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2015] [Revised: 05/05/2015] [Accepted: 05/10/2015] [Indexed: 11/04/2022]
Abstract
OBJECTIVES The study investigated whether renal complications affected the efficacy and safety of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase. METHODS Fifty-seven patients with SLE (A: 30 cases with renal complication, B: 27 cases without renal complications) were included. The presence of renal complications was defined as proteinuria ≥0.5 g/day and lupus nephritis on renal biopsy. Major outcome measures included SLE disease activity index (SLEDAI), steroid dose, serum anti-dsDNA Ab, C3 and creatinine (Cr) levels and estimated glomerular filtration rate (eGFR). The patient's background factors included age, gender, disease duration and ACE-I/angiotensin II receptor blocker and statin therapies. We compared these outcome measures pre treatment and after 1 year of treatment. RESULTS The SLEDAI and serum C3 levels improved in both groups from pretreatment period to post-treatment period: from 7.2±5.0 to 2.8±2.3 in A and 6.4±3.8 to 2.4±2.2 in B, p<0.001, and from 65.9±24.6 to 77.7±18.2 mg/dL in A and 81.8±23.0 to 90.6±19.4 mg/dL in B, p=0.002, respectively. The anti-dsDNA antibody level was reduced, and the serum Cr and eGFR levels were slightly elevated. No patients developed end-stage renal failure that required artificial dialysis. CONCLUSIONS Tacrolimus combination therapy had additive beneficial effects on reduced proteinuria and increased serum C3 levels in patients with SLE with renal complications during a maintenance phase.
Collapse
Affiliation(s)
- Sho Ishii
- Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan
| | - Yusuke Miwa
- Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan
| | - Kumiko Otsuka
- Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan
| | - Shinichiro Nishimi
- Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan
| | - Airi Nishimi
- Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan
| | - Mayu Saito
- Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan
| | - Yoko Miura
- Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan
| | - Nao Oguro
- Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan
| | - Takahiro Tokunaga
- Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan
| | - Ryo Takahashi
- Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine , Showa University School of Medicine , Tokyo , Japan
| |
Collapse
|
41
|
Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, Kawai S, Kawakami A, Koike T, Miyahara H, Miyamoto T, Munakata Y, Murasawa A, Nishimoto N, Ogawa N, Ojima T, Sano H, Shi K, Shono E, Suematsu E, Takahashi H, Tanaka Y, Tsukamoto H, Nomura A. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study. J Rheumatol 2015; 42:799-809. [PMID: 25834203 DOI: 10.3899/jrheum.140665] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/27/2015] [Indexed: 01/07/2023]
Abstract
OBJECTIVE To evaluate the longterm safety and efficacy of subcutaneous tocilizumab (TCZ-SC) as monotherapy in patients with rheumatoid arthritis (RA). METHODS Of 346 patients who received 24 weeks of double-blind treatment with either TCZ-SC monotherapy, 162 mg every 2 weeks (q2w); or intravenous TCZ (TCZ-IV) monotherapy, 8 mg/kg every 4 weeks; 319 patients continued to receive TCZ-SC q2w in the 84-week open-label extension (OLE) of the MUSASHI study (JAPICCTI-101117). Efficacy, safety, and immunogenicity were evaluated for all patients treated with TCZ during 108 weeks. RESULTS The proportions of patients who achieved American College of Rheumatology 20/50/70 responses, low disease activity [28-joint Disease Activity Score (DAS28) ≤ 3.2], or remission (DAS28 < 2.6) at Week 24 were maintained until Week 108. The incidences of adverse events and serious adverse events were 498.3 and 16.9 per 100 patient-years (PY), respectively. The overall safety of TCZ-SC monotherapy was similar to that of TCZ-IV monotherapy. Rates of injection site reactions (ISR) through 108 weeks remained similar to rates through 24 weeks. ISR were mild and did not cause any patient withdrawals. No serious hypersensitivity events (including anaphylactic reactions) occurred. Anti-TCZ antibodies were present in 2.1% of patients treated with TCZ-SC monotherapy. CONCLUSION TCZ-SC monotherapy maintained a favorable safety profile and consistent efficacy throughout the 108-week study. Like TCZ-IV, TCZ-SC could provide an additional treatment option for patients with RA.
Collapse
Affiliation(s)
- Atsushi Ogata
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Koichi Amano
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Hiroaki Dobashi
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Masayuki Inoo
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Tomonori Ishii
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Tsuyoshi Kasama
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Shinichi Kawai
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Atsushi Kawakami
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Tatsuya Koike
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Hisaaki Miyahara
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Toshiaki Miyamoto
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Yasuhiko Munakata
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Akira Murasawa
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Norihiro Nishimoto
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Noriyoshi Ogawa
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Tomohiro Ojima
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Hajime Sano
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Kenrin Shi
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Eisuke Shono
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Eiichi Suematsu
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Hiroki Takahashi
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Yoshiya Tanaka
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Hiroshi Tsukamoto
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | - Akira Nomura
- From the Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine and Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, Osaka; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama; Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University; Department of Rheumatology, Utazu-Hama Clinic, Kagawa; Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai; Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo; Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; Department of Rheumatosurgery, Osaka City University, Graduate School of Medicine, Osaka; Department of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka; Department of Rheumatology, Seirei Hamamatsu General Hospital, Shizuoka; Munakata Yasuhiko Clinic, Miyagi; Department of Rheumatology, Niigata Rheumatic Center, Niigata; Osaka Rheumatology Clinic, Osaka; Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka; Department of Orthopedic Surgery, Fukui General Hospital, Fukui; Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo; Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka; Shono Rheumatology Clinic, Fukuoka; First Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka; Department of Medicine and Biosy
| | | |
Collapse
|
42
|
Abstract
This is the first report of the efficacy of leukocytapheresis (LCAP) in a patient with refractory adult onset Still's disease (AOSD) during pregnancy. A 32-year-old Chinese pregnant woman with AOSD who had been treated with prednisolone failed to achieve disease stabilization. The patient's disease was successfully controlled with the initiation of LCAP. Subsequently, she gave birth via Caesarean section to a 1,878 g baby boy at 34 weeks of gestation while maintaining remission. We conclude that LCAP is an alternative treatment in pregnant patients with refractory AOSD, particularly in those concerned about potential teratogenic and other adverse effects.
Collapse
Affiliation(s)
- Tsuyoshi Odai
- Division of General Internal Medicine, Ebina General Hospital, Japan
| | | | | | | | | |
Collapse
|
43
|
Miwa Y, Nishimi A, Nishimi S, Saito M, Tokunaga T, Yanai R, Takahashi R, Wakabayashi K, Kasama T, Hosaka M. Combined infliximab and methotrexate treatment improves the depressive state in rheumatoid arthritis patients more effectively than methotrexate alone. Eur J Rheumatol 2014; 1:147-149. [PMID: 27708901 PMCID: PMC5042244 DOI: 10.5152/eurjrheumatol.2014.140074] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2014] [Accepted: 09/03/2014] [Indexed: 11/22/2022] Open
Abstract
OBJECTIVE Rheumatoid arthritis (RA) patients have a greater depressive tendency than normal subjects, and infliximab is known to provide quick therapeutic effects and to have high bioavailability for RA. We therefore investigated whether the depressive state of RA patients would be improved by infliximab. MATERIAL AND METHODS The Self-Rating Depression Scale (SDS) was used to evaluate 34 RA patients before and 14 or 30 weeks after inflixi mab treatment using the SDS and Disease Activity Score (DAS) 28. The SDS and DAS28 results before and after treatment were compared. RESULTS We also included 42 cases treated with methotrexate as the control group. The SDS decreased in both groups, and the intraindividual vari ability was p<0.001, indicating that the drugs had significantly different effects on the SDS. The DAS tended to decrease in both groups, but the intraindividual variability was p=0.199, indicating no difference between the two drugs. CONCLUSION This study is a preliminary study, but the data suggest that infliximab may reduce RA disease activity and improve the depressive state.
Collapse
Affiliation(s)
- Yusuke Miwa
- Department of Rheumatology, Showa University Faculty of Medicine, Tokyo, Japan
| | - Airi Nishimi
- Department of Rheumatology, Showa University Faculty of Medicine, Tokyo, Japan
| | - Shinichiro Nishimi
- Department of Rheumatology, Showa University Faculty of Medicine, Tokyo, Japan
| | - Mayu Saito
- Department of Rheumatology, Showa University Faculty of Medicine, Tokyo, Japan
| | - Takahiro Tokunaga
- Department of Rheumatology, Showa University Faculty of Medicine, Tokyo, Japan
| | - Ryo Yanai
- Department of Rheumatology, Showa University Faculty of Medicine, Tokyo, Japan
| | - Ryo Takahashi
- Department of Rheumatology, Showa University Faculty of Medicine, Tokyo, Japan
| | | | - Tsuyoshi Kasama
- Department of Rheumatology, Showa University Faculty of Medicine, Tokyo, Japan
| | - Michio Hosaka
- Department of Rheumatology, Clini of Katsuyama, Yamanashi, Japan
| |
Collapse
|
44
|
Otsuka K, Miwa Y, Oguro N, Miura Y, Ishii S, Seki S, Furuya H, Yanai R, Takahashi R, Wakabayashi K, Isozaki T, Yajima N, Kasama T. AB0493 Tacrolimus Therapy for Systemic Lupus Erythematosus with or without Renal Involvement during the Maintenance Phase. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
45
|
Yamanaka H, Seto Y, Nagaoka S, Bae SC, Kasama T, Lee SK, Kobayashi H, Nishioka Y, Tanaka Y, Takeuchi T. THU0169 Discontinuation of Etanercept in Early Rheumatoid Arthritis Patients who Have Achieved Sustained Remission: Results of the Randomized Controlled Trial in Period 2 of the Encourage Study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2429] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
46
|
Takahashi R, Isojima S, Umemura M, Miura Y, Oguro N, Ishii S, Seki S, Tokunaga T, Tsukamoto H, Furuya H, Yanai R, Kasama T. Serum anticyclic citrullinated protein antibody titers are correlated with the response to biological agents in patients with rheumatoid arthritis. Open Access Rheumatol 2014; 6:57-64. [PMID: 27790035 PMCID: PMC5045110 DOI: 10.2147/oarrr.s58772] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Anticyclic citrullinated protein antibody (ACPA) is known as an important indicator for diagnosis of rheumatoid arthritis (RA). Our aim was to examine the relationship between the serum ACPA titer at baseline and responsiveness to biological agents (antagonists of either tumor necrosis factor or interleukin 6) in patients with RA. ACPA was measured using second-generation chemiluminescent enzyme immunoassay. Disease activity was assessed using disease activity scores 28. Fifty-seven RA patients with biological agents were enrolled, and the median ACPA titer at baseline was 110.0 U/mL. The median ACPA titer was 23.3 U/mL and 183.0 U/mL in the good and moderate response groups, respectively, which were significantly lower than in the no response group (404.0 U/mL). In addition, 69.2% and 26.9% of patients with low (<100 U/mL) and moderate (100–499 U/mL) basal ACPA titers showed a moderate to good response. Of the patients with higher (≥500 U/mL) basal ACPA titers, only 14.0% and 42.5% showed a good or moderate response, respectively. The remission rate was 77.8% in the ACPA-negative, which was significantly higher than the rate of 25% in the ACPA-positive patients. The results suggest that the ACPA titers are correlated with the efficacy of the biological agents used in patients with RA.
Collapse
Affiliation(s)
- Ryo Takahashi
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Sakiko Isojima
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Masayu Umemura
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Yoko Miura
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Nao Oguro
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Syo Ishii
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Shinya Seki
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Takahiro Tokunaga
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Hiroyuki Tsukamoto
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Hidekazu Furuya
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Ryo Yanai
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Tsuyoshi Kasama
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| |
Collapse
|
47
|
Hirohata S, Kasama T, Kawahito Y, Takabayashi K. Efficacy of anti-ribosomal P protein antibody testing for diagnosis of systemic lupus erythematosus. Mod Rheumatol 2014; 24:939-44. [DOI: 10.3109/14397595.2014.884529] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
48
|
Chen YZ, Bovet N, Kasama T, Gao WW, Yazdi S, Ma C, Pryds N, Linderoth S. Room temperature formation of high-mobility two-dimensional electron gases at crystalline complex oxide interfaces. Adv Mater 2014; 26:1462-1467. [PMID: 24338762 DOI: 10.1002/adma.201304634] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/15/2013] [Indexed: 06/03/2023]
Abstract
Well-controlled sub-unit-cell layer-bylayer epitaxial growth of spinel alumina is achieved at room temperature on a TiO2 -terminated SrTiO3 single-crystalline substrate. By tailoring the interface redox reaction, 2D electron gases with mobilities exceeding 3000 cm 2 V(-1) s(-1) are achieved at this novel oxide interface.
Collapse
Affiliation(s)
- Y Z Chen
- Department of Energy Conversion and Storage, Technical University of Denmark, Risø Campus, 4000, Roskilde, Denmark
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Umemura M, Miwa Y, Yanai R, Isojima S, Tokunaga T, Tsukamoto H, Takahashi R, Yajima N, Kasama T, Takahashi N, Sueki H, Yamaguchi S, Arai K, Takeuchi Y, Ohike N, Norose T, Yamochi-Onizuka T, Takimoto M. A case of Degos disease: demonstration of C5b-9-mediated vascular injury. Mod Rheumatol 2014; 25:480-3. [PMID: 24506660 DOI: 10.3109/14397595.2013.874761] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A 68-year-old Japanese male presented with atrophic erythematous white lesions with peripheral dark reddish rims on his back. Multiple ulcers were detected from his stomach to his large intestine using endoscopy. Although the patient was given high doses of a steroid, aspirin, dipyridamole, and intravenous immunoglobulin therapy, he died of gastrointestinal hemorrhage, perforation and septic shock. An autopsy examination revealed pauci-inflammatory thrombotic microangiopathy with endothelial cell injury, fibrous occlusive arteriopathy, and vascular C5b-9 deposition in the wall of the gastrointestinal tract from the esophagus to the large intestine as well as in the dermis of the skin.
Collapse
Affiliation(s)
- Masayu Umemura
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine , Tokyo , Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, Takeuchi T. SAT0131 Continuation/discontinuation of methotrexate and clinical response to etanercept determine the radiographic progression/repair in patients with rheumatoid arthritis: A subanalysis of 52-week results from the JESMR study:. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.3078] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|